Pharmacogenomics: Role in medicines approval and clinical use

Public Health Genomics

Volumn 13, Issue 5, 2010, Pages 284-291

  Novelli, G ^a,b,d   Borgiani, P ^a   Ciccacci, C ^a   Di Daniele, N ^a   Sirugo, G ^b   Papaluca Amati, M ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b San Pietro Hospital   (Italy)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Abacavir; CYP2C9; Genomic biomarkers; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphisms; VKORC1; Warfarin

Indexed keywords

ABACAVIR; CYTOCHROME P450 2C9; HLA B57 ANTIGEN; KIDNEY INJURY MOLECULE 1; PHARMACOLOGICAL BIOMARKER; WARFARIN;

DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG RESPONSE; DRUG USE; GENE EXPRESSION REGULATION; HUMAN; HYPERSENSITIVITY; NEPHROTOXICITY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG APPROVAL; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77954243597     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245271     Document Type: Review

References (41)

1. Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
2. McCamish M, Izumi R: Perspectives on development of a combination pharmacogenomic diagnostic and drug product. Pharmacogenomics 2006; 7: 1045-1049.
3. Davis RL, Khoury MJ: A public health approach to pharmacogenomics and genebased diagnostic tests. Pharmacogenomics 2006; 7: 331-337.
4. Shabo A: Clinical genomics data standards for pharmacogenetics and pharmacogenomics. Pharmacogenomics 2006; 7: 247-253.
5. van Aken J, Schmedders M, Feuerstein G, Kollek R: Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003; 3: 149-155.
6. Roses AD: Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-549.
7. Wagner JA, Williams SA, Webster CJ: Biomarkers and surrogate end points for fit-forpurpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007; 81: 104-107.
8. Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E: Genetic tests and genomic biomarkers: regulation, qualification and validation. CCMBM 2008; 103: 371-381.
9. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
10. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
11. Sconce EA, Kamali F: Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol 2006; 77: 457-462.
12. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
13. Yin T, Miyata T: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - Rationale and perspectives. Thromb Res 2007; 120: 1-10.
14. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S. (Pubitemid 39297955)
15. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-544.
16. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
17. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
18. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-691.
19. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270.
20. DAndrea G, DAmbrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649.
21. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E: Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211 .
22. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G: Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 2007; 8: 1545-1550.
23. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R J: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-178.
24. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
25. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS, ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use: Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10: 139-150.
26. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
27. Wu AH: Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007; 8: 851-861.
28. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK: CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
29. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P: A genome-wide association study confirms VKORC1 , CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5:e1000433.
30. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G: CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10: 261-266.
31. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT: Association between presence of HLA-B * 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
32. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
33. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A: PREDICT-1 Study Team. HLA-B * 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
34. Martin AM, Nolan D, Mallal S: HLA-B * 5701 typing by sequence-specific amplification: validation and comparison with sequencebased typing. Tissue Antigens 2005; 65: 571-574.
35. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D; on behalf of the CNA106030 Study Team: PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat 2008; 7: 121-129.
36. Bennett WM: Drug nephrotoxicity: an overview. Ren Fail 1997; 19: 221-224.
37. Khan KNM, Alden CL: Kidney; in Haschek WM, Rousseaux CG, Wallig MA (eds): Handbook of Toxicological Pathology, ed 2, San Diego, CA, Academic Press, 2002, pp 255-330.
38. Duarte CG, Preuss HG: Assessment of renal function - glomerular and tubular. Clin Lab Med 1993; 13: 33-52.
39. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A: Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin A in vivo and in vitro. Toxicol Sci 2008; 103: 371-381.
40. Prozialeck WC, Vaidya VS, Liu J, Waalkes MP, Edwards JR, Lamar PC, Bernard AM, Dumont X, Bonventre JV: Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int 2007; 72: 985-993.
41. Wang EJ, Snyder RD, Fielden MR, Smith RJ, Gu YZ: Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008; 246: 91-100.